We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Eagle Pharmaceuticals Inc | NASDAQ:EGRX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.005 | -0.11% | 4.745 | 4.73 | 4.76 | 4.78 | 4.69 | 4.71 | 21,119 | 17:12:20 |
Date: | Wednesday, September 27, 2023 |
Time: | 2.25PM ET |
Webcast: | Click here |
To schedule a 1x1 meeting with management, please contact corporateaccess@cantor.com.
The webcast of the presentation will be accessible for 90 days thereafter, via the Company’s website at www.eagleus.com, under the Investors section.
About Eagle Pharmaceuticals, Inc. Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), and BYFAVO® and BARHEMSYS® through its wholly owned subsidiary Acacia Pharma Inc. Eagle’s oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states, and the company is focused on developing medicines with the potential to become part of the personalized medicine paradigm in cancer care. Additional information is available on Eagle’s website at www.eagleus.com.
Investor Relations for Eagle Pharmaceuticals, Inc.: Lisa M. WilsonIn-Site Communications, Inc. T: 212-452-2793 E: lwilson@insitecony.com
Public Relations for Eagle Pharmaceuticals, Inc.:Faith Pomeroy-WardT: 817-807-8044E: faith@eagleus.com
1 Year Eagle Pharmaceuticals Chart |
1 Month Eagle Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions